Novozymes Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Novozymes kazançlarla iyi bir şekilde karşılanan, 1.52% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

1.5%

Temettü verimi

-0.04%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.5%
Gelecekteki Temettü Verimi	2.0%
Temettü Büyümesi	6.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	65%

Son temettü ve geri alım güncellemeleri

Recent updates

Anlatı Güncellemesi • Sep 07

NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential

The analyst fair value estimate for Novozymes is now DKK 491.93, up DKK 20.88 from the prior DKK 471.06. Analysts are factoring in updated assumptions that align with a series of recent price target increases on Novonesis in the DKK 490 to DKK 535 range.

Anlatı Güncellemesi • Aug 24

NSIS B: Elevated Expectations Will Hinge On Successful MicroBioGen Integration

The analyst fair value estimate for Novozymes has been raised from DKK 400 to DKK 414. This change reflects a series of higher DKK 415 to DKK 535 price targets from several firms, along with analyst views that support slightly stronger margin and P/E assumptions despite a marginally higher discount rate and modestly softer revenue growth inputs.

Anlatı Güncellemesi • Aug 10

NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential

The analyst fair value estimate for Novozymes has increased from DKK 520 to DKK 540, as analysts cite a series of higher Street price targets in the DKK 460 to DKK 552 range and improving views on the company following recent rating upgrades. Analyst Commentary on Novozymes Recent research on Novozymes, through the merged Novonesis entity, points to a more constructive tone from several bullish analysts.

Anlatı Güncellemesi • Jul 24

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential

The analyst price target for Novozymes has been reset to DKK 520, with analysts pointing to updated assumptions on growth, profitability and valuation multiples as the main drivers of the change. Analyst Commentary Recent Street research on Novozymes, now part of Novonesis, shows a series of constructive shifts in sentiment, with several firms revisiting their assumptions on valuation, execution and growth.

Anlatı Güncellemesi • Jul 10

NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China

The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis. Analyst Commentary Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk.

Anlatı Güncellemesi • Jun 26

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.

Analiz Makalesi • Jun 22

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NSIS B şirketinin temettü ödemeleri son 10 yıldır dalgalı seyretti.

Büyüyen Temettü: NSIS B şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Novozymes Piyasaya Karşı Temettü Getirisi

NSIS B temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NSIS B)	1.5%
Pazarın Alt %25'i (DK)	1.4%
Pazarın En İyi %25'i (DK)	3.9%
Sektör Ortalaması (Chemicals)	3.1%
Analist tahmini (NSIS B) (3 yıla kadar)	2.0%

Önemli Temettü: NSIS B 'in temettüsü ( 1.52% ), Danish piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.43% ) daha yüksektir.

Yüksek Temettü: NSIS B 'in temettüsü ( 1.52% ), Danish piyasasındaki temettü ödeyenlerin en üst %25'ine ( 3.91% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Makul ödeme oranı ( 65.4% ) ile NSIS B 'un temettü ödemeleri kazançlarla karşılanmaktadır.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 52.7% ) ile NSIS B 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/14 11:38
Gün Sonu Hisse Fiyatı	2026/09/11 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Novozymes A/S 28 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Cezara Lozneanu	Barclays
Alexander Sloane	Barclays
Sebastian Satz	Barclays

Novozymes Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

First half dividend of kr.2.35 announced

Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026

Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.

Novonesis A/S Approves Dividend on A and B Share

Upcoming dividend of kr.4.25 per share

Dividend of kr.4.25 announced

Recent updates

NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential

Novozymes Commits €600 Million to Expand Enzyme Facility in India by 2030

Novozymes A/S to Report Fiscal Year 2026 Results on Feb 11, 2027

NSIS B: Elevated Expectations Will Hinge On Successful MicroBioGen Integration

First half dividend of kr.2.35 announced

Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026

Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.

Second quarter 2026 earnings: EPS misses analyst expectations

Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising Quality

Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd.

Novozymes Advances Yeast R&D With Agreement to Acquire Remaining MicroBioGen Stake

NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential

NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

First quarter 2026 earnings: EPS exceeds analyst expectations

Novozymes Delivers 7% Organic Sales Growth and Expands Capacity in Q1 2026

Novonesis A/S Approves Dividend on A and B Share

Upcoming dividend of kr.4.25 per share

Full year 2025 earnings: EPS misses analyst expectations

Dividend of kr.4.25 announced

Vice Chair of the Board recently bought kr.1.0m worth of stock

Novozymes A/S, Annual General Meeting, Mar 23, 2026

Novozymes A/S Proposes Dividend for Full Year 2025

Now 21% overvalued

Third quarter 2025 earnings: EPS misses analyst expectations

Novozymes A/S Revises Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 20%

Now 20% undervalued after recent price drop

Vice Chair of the Board recently bought kr.1.2m worth of stock

First half dividend of kr.2.25 announced

Consensus EPS estimates increase by 15%

New minor risk - Dividend sustainability

Novonesis A/S Approves Interim Dividend for First Half of 2025

Now 20% undervalued

New major risk - Revenue and earnings growth

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

First quarter 2025 earnings: EPS exceeds analyst expectations

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Less than half of directors are independent

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Now 24% undervalued after recent price drop

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Now 20% undervalued after recent price drop

New minor risk - Dividend sustainability

Novonesis A/S Announces Board Changes

Full year 2024 earnings: EPS misses analyst expectations

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%